Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Meny

Test for dMMR/MSI-H

When considering immunotherapy for patients with endometrial cancer (EC), testing for dMMR/MSI-H will be crucial to enable treatment.1

ESMO recommends MMR/MSI testing in EC to determine eligibility for treatment with immunotherapy

MMR/MSI testing should be done using one of several readily accessible testing methods:1

Image of microscope used for immunohistochemistry.

(1)

IHC—RECOMMENDED STEP FOR DETECTING dMMR*

*In some circumstances, pathologists may request an additional molecular test, eg NGS or PCR, to verify the IHC result.

KNOWING A PATIENT’S MMR/MSI STATUS PROVIDES A MORE COMPLETE GENOMIC PICTURE OF THEIR EC AND THE OPPORTUNITY FOR USE OF IMMUNOTHERAPY

Establish a practice-based protocol

Create a seamless testing and reporting process with your pathology partner.1

  • CHECK patients’ medical records for existing results
  • INTEGRATE MMR/MSI testing into your patient workflow
  • UPDATE your hospital files requisition form to ensure MMR/MSI testing occurs

IDENTIFY YOUR PATIENTS WHO MAY BENEFIT FROM IMMUNOTHERAPY BY TESTING FOR dMMR/MSI-H

Abbreviations

dMMR, mismatch repair deficient=defekt mismatch repair; ESMO, European Society for Medical Oncology; IHC, immunohistochemistry=immunhistokemi; MMR, mismatch repair=mismatch repair-proteiner; MSI, microsatellite instability=mikrosatellitinstabilitet; MSI-H, microsatellite instability-high=hög mikrosatellitinstabilitet; NGS, next-generation sequencing=nästa generations sekvensering; PCR, polymerase chain reaction=polymeraskedjereaktion.

References

  1. Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232-1243.

Senast uppdaterad: Juni 2022. NP-SE-DST-WCNT-220005